title: New antiaxillary odour deodorant made with antimicrobial Ag-zeolite (silver-exchanged zeolite).
abstract: The causative substances for axillary osmidrosis, which are often found in apocrine sweat, are the decomposed/denatured products of short-chain fatty acid and other biological metabolite compounds produced by axillary-resident bacteria. Conventional underarm deodorants suppress the process of odour production mostly by the following mechanism: (1) suppression of perspiration, (2) reduction in numbers of resident bacteria, (3) deodorization and (4) masking. The most important and effective method to reduce odour is to suppress the growth of resident bacteria with antimicrobials, which have several drawbacks, especially in their safety aspect. To solve these problems, we focused on Ag-zeolite (silver-exchanged zeolite) that hold stable Ag, an inorganic bactericidal agent, in its structure, and therefore, poses less risk in safety. Its bactericidal effect on skin-resident bacteria was found to be excellent and comparable with that of triclosan, a most frequently used organic antimicrobial in this product category. The dose-response study of Ag-zeolite powder spray (0-40 w/w%) using 39 volunteers revealed that 5-40 w/w% Ag-zeolite could show a sufficient antimicrobial effect against skin-resident bacteria. The comparison study using 0.2 w/w% triclosan as the control and 10 w/w% Ag-zeolite indicated that: (1) one application of the powder spray containing 10 w/w% Ag-zeolite could show a sufficient antimicrobial effect against the resident bacteria and its effect continued for 24 h, (2) a powder spray containing 0.2 w/w% triclosan was unable to show a sufficient antimicrobial effect, and (3) no adverse event was observed. These studies show that Ag-zeolite has a superior antimicrobial ability that is rarely found in conventional antimicrobials used in deodorant products and a strong antiaxillary odour deodorant ability because of its long-lasting effect. During clinical study, patch tests with humans and other clinical studies of this product showed no adverse events related to the treatment with the Ag-zeolite product.
authors.affiliation: Basic Research Center, FT Shiseido Co., Tuzuki-ku Yokohama-shi 224-8858, Japan. toshihiko.nakane@to.shiseido.co.jp
authors.forename: T
authors.initials: T
authors.lastname: Nakane
authors.forename: H
authors.initials: H
authors.lastname: Gomyo
authors.forename: I
authors.initials: I
authors.lastname: Sasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kimoto
authors.forename: N
authors.initials: N
authors.lastname: Hanzawa
authors.forename: Y
authors.initials: Y
authors.lastname: Teshima
authors.forename: T
authors.initials: T
authors.lastname: Namba